JPRN-jRCT1080222407未知Unknown
otriga Granular Capsules special drug use surveillance (long-term use survey)
TAKEDA PHARMACEUTICAL COMPANY LTD.0 个研究点目标入组 3,084 人开始时间: 2014年2月27日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 发起方
- 入组人数
- 3,084
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients with hyperlipidemia
排除标准
- •(1) Patients with hemorrhage (e.g., hemophilia, capillary fragility, gastrointestinal ulcer, urinary tract hemorrhage, hemoptysis, or vitreous hemorrhage)
- •(2) Patients with a history of hypersensitivity to ingredients in Lotriga Granular Capsules
研究者
相似试验
未知
Unknown
iovel Combination Tablets special drug use surveillance Long-term use in patients with type 2 diabetes mellitusJPRN-jRCT1080222253TAKEDA PHARMACEUTICAL COMPANY LTD.3,000
招募中
不适用
Special Drug Use Surveillance of Rozlytrek Capsule in Pediatric Patients - Advanced or recurrent solid tumors with NTRK gene fusionsAdvanced or recurrent solid tumors with NTRK gene fusionsJPRN-UMIN000039670Chugai Pharmaceutical Co. Ltd.10
未知
Unknown
EGEND study (Lansoprazole effectiveness on GERD patients with dyspepsia symptoms)Gastroesophageal reflux disease with dyspepsia symptomsJPRN-jRCT1080222261TAKEDA PHARMACEUTICAL COMPANY LTD.15,000
招募中
Unknown
Post-marketing Surveillance Protocol Number;CLCZ696A1402HypertensionJPRN-jRCT2031230283Sugigmoto Toshiya1,000
招募中
不适用
Special drug use Surveillance for EFIENT Tablets- Patient with ischemic cerebrovascular disease with a high risk of ischemic strokeIschemic cerebrovascular disease (associated with large-artery atherosclerosis or small-vessel occluJPRN-jRCT2031220131Matsuoka Yomei1,200